|
1
|
D'Haens G, Sandborn WJ, Feagan BG, Geboes
K, Hanauer SB, Irvine EJ, Lémann M, Marteau P, Rutgeerts P,
Schölmerich J, et al: A review of activity indices and efficacy end
points for clinical trials of medical therapy in adults with
ulcerative colitis. Gastroenterology. 132:763–786. 2007.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Magro F, Rodrigues A, Vieira AI, Portela
F, Cremers I, Cotter J, Correia L, Duarte MA, Tavares ML, Lago P,
et al: Review of the disease course among adult ulcerative colitis
population-based longitudinal cohorts. Inflamm Bowel Dis.
18:573–583. 2012.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Sandborn WJ, Hanauer S, Van Assche G,
Panés J, Wilson S, Petersson J and Panaccione R: Treating beyond
symptoms with a view to improving patient outcomes in inflammatory
bowel diseases. J Crohn's Colitis. 8:927–935. 2014.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Ardizzone S, Cassinotti A, Duca P, Mazzali
C, Penati C, Manes G, Marmo R, Massari A, Molteni P, Maconi G, et
al: Mucosal healing predicts late outcomes after the first course
of corticosteroids for newly diagnosed ulcerative colitis. Clin
Gastroenterol Hepatol. 9:483–489.e3. 2011.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Frøslie KF, Jahnsen J, Moum BA and Vatn
MH: IBSEN Group. Mucosal healing in inflammatory bowel disease:
results from a Norwegian population-based cohort. Gastroenterology.
133:412–422. 2007.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Peyrin-Biroulet L, Ferrante M, Magro F,
Campbell S, Franchimont D, Fidder H, Strid H, Ardizzone S,
Veereman-Wauters G, Chevaux JB, et al: Scientific Committee of the
European Crohn's and Colitis Organization: Results from the 2nd
Scientific Workshop of the ECCO. I: Impact of mucosal healing on
the course of inflammatory bowel disease. J Crohns Colitis.
5:477–483. 2011.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Walsh A, Palmer R and Travis S: Mucosal
healing as a target of therapy for colonic inflammatory bowel
disease and methods to score disease activity. Gastrointest Endosc
Clin N Am. 24:367–378. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Colombel JF, Rutgeerts P, Reinisch W,
Esser D, Wang Y, Lang Y, Marano CW, Strauss R, Oddens BJ, Feagan
BG, et al: Early mucosal healing with infliximab is associated with
improved long-term clinical outcomes in ulcerative colitis.
Gastroenterology. 141:1194–1201. 2011.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Mazzuoli S, Guglielmi FW, Antonelli E,
Salemme M, Bassotti G and Villanacci V: Definition and evaluation
of mucosal healing in clinical practice. Dig Liver Dis. 45:969–977.
2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Nakarai A, Kato J, Hiraoka S, Inokuchi T,
Takei D, Moritou Y, Akita M, Takahashi S, Hori K, Harada K, et al:
Prognosis of ulcerative colitis differs between patients with
complete and partial mucosal healing, which can be predicted from
the platelet count. World J Gastroenterol. 20:18367–18374.
2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Yokoyama K, Kobayashi K, Mukae M, Sada M
and Koizumi W: Clinical study of the relation between mucosal
healing and long-term outcomes in ulcerative colitis. Gastroenterol
Res Pract. 2013(192794)2013.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Oliva S, Di Nardo G, Hassan C, Spada C,
Aloi M, Ferrari F, Redler A, Costamagna G and Cucchiara S:
Second-generation colon capsule endoscopy vs. colonoscopy in
pediatric ulcerative colitis: A pilot study. Endoscopy. 46:485–492.
2014.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Judd TA, Day AS, Lemberg DA, Turner D and
Leach ST: Update of fecal markers of inflammation in inflammatory
bowel disease. J Gastroenterol Hepatol. 26:1493–1499.
2011.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Wright EK, Kamm MA, De Cruz P, Hamilton
AL, Ritchie KJ, Keenan JI, Leach S, Burgess L, Aitchison A, Gorelik
A, et al: Comparison of fecal inflammatory markers in Crohn's
disease. Inflamm Bowel Dis. 22:1086–1094. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Kato J, Hiraoka S, Nakarai A, Takashima S,
Inokuchi T and Ichinose M: Fecal immunochemical test as a biomarker
for inflammatory bowel diseases: Can it rival fecal calprotectin?
Intest Res. 14:5–14. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Ma C, Lumb R, Walker EV, Foshaug RR, Dang
TT, Verma S, Huang VW, Kroeker KI, Wong K, Dieleman LA, et al:
Noninvasive fecal immunochemical testing and fecal calprotectin
predict mucosal healing in inflammatory bowel disease: a
prospective cohort study. Inflamm Bowel Dis. 23:1643–1649.
2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Nakarai A, Kato J, Hiraoka S, Kuriyama M,
Akita M, Hirakawa T, Okada H and Yamamoto K: Evaluation of mucosal
healing of ulcerative colitis by a quantitative fecal
immunochemical test. Am J Gastroenterol. 108:83–89. 2013.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Takashima S, Kato J, Hiraoka S, Nakarai A,
Takei D, Inokuchi T, Sugihara Y, Takahara M, Harada K, Okada H, et
al: Evaluation of mucosal healing in ulcerative colitis by fecal
calprotectin vs. fecal immunochemical test. Am J Gastroenterol.
110:873–880. 2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Lee YW, Lee KM, Lee JM, Chung YY, Kim DB,
Kim YJ, Chung WC and Paik CN: The usefulness of fecal calprotectin
in assessing inflammatory bowel disease activity. Korean J Intern
Med (Korean Assoc Intern Med). 34:72–80. 2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Kristensen V, Klepp P, Cvancarova M,
Røseth A, Skar V and Moum B: Prediction of endoscopic disease
activity in ulcerative colitis by two different assays for fecal
calprotectin. J Crohn's Colitis. 9:164–169. 2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Hiraoka S, Inokuchi T, Takashima S, Takei
D, Sugihara Y, Takahara M, Harada K, Seki Y, Watanabe K and Okada
H: P0824 A novel fecal calprotectin assay using the latex
agglutination turbidimetric immunoassay is useful for ulcerative
colitis patients in evaluation of mucosal healing. United European
Gastroenterol J. 4(A435)2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Lobatón T, Rodríguez-Moranta F, Lopez A,
Sánchez E, Rodríguez-Alonso L and Guardiola J: A new rapid
quantitative test for fecal calprotectin predicts endoscopic
activity in ulcerative colitis. Inflamm Bowel Dis. 19:1034–1042.
2013.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Theede K, Holck S, Ibsen P, Ladelund S,
Nordgaard-Lassen I and Nielsen AM: Level of fecal calprotectin
correlates with endoscopic and histologic inflammation and
identifies patients with mucosal healing in ulcerative colitis.
Clin Gastroenterol Hepatol. 13:1929–1936. 2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Mak WY, Buisson A, Andersen MJ Jr, Lei D,
Pekow J, Cohen RD, Kahn SA, Pereira B and Rubin DT: Fecal
calprotectin in assessing endoscopic and histological remission in
patients with ulcerative colitis. Dig Dis Sci. 63:1294–1301.
2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Ryu DG, Kim HW, Park SB, Kang DH, Choi CW,
Kim SJ and Nam HS: Clinical implications of fecal calprotectin and
fecal immunochemical test on mucosal status in patients with
ulcerative colitis. Medicine (Baltimore). 98(e17080)2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Whiting PF, Rutjes AW, Westwood ME,
Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA and Bossuyt
PM: QUADAS-2 Group. QUADAS-2: A revised tool for the quality
assessment of diagnostic accuracy studies. Ann Intern Med.
155:529–536. 2011.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Dai C, Jiang M, Sun MJ and Cao Q: Fecal
immunochemical test for predicting mucosal healing in ulcerative
colitis patients: A systematic review and meta-analysis. J
Gastroenterol Hepatol. 33:990–997. 2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Auge JM, Pellise M, Escudero JM, Hernandez
C, Andreu M, Grau J, Buron A, López-Cerón M, Bessa X,
Serradesanferm A, et al: PROCOLON Group: Risk stratification for
advanced colorectal neoplasia according to fecal hemoglobin
concentration in a colorectal cancer screening program.
Gastroenterology. 147:628–636.e1. 2014.PubMed/NCBI View Article : Google Scholar
|
|
29
|
D'Haens G, Ferrante M, Vermeire S, Baert
F, Noman M, Moortgat L, Geens P, Iwens D, Aerden I, Van Assche G,
et al: Fecal calprotectin is a surrogate marker for endoscopic
lesions in inflammatory bowel disease. Inflamm Bowel Dis.
18:2218–2224. 2012.PubMed/NCBI View Article : Google Scholar
|
|
30
|
García-Sánchez V, Iglesias-Flores E,
González R, Gisbert JP, Gallardo-Valverde JM, González-Galilea A,
Naranjo-Rodríguez A, de Dios-Vega JF, Muntané J and Gómez-Camacho
F: Does fecal calprotectin predict relapse in patients with Crohn's
disease and ulcerative colitis? J Crohn's Colitis. 4:144–152.
2010.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Lin JF, Chen JM, Zuo JH, Yu A, Xiao ZJ,
Deng FH, Nie B and Jiang B: Meta-analysis: Fecal calprotectin for
assessment of inflammatory bowel disease activity. Inflamm Bowel
Dis. 20:1407–1415. 2014.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Mosli MH, Zou G, Garg SK, Feagan SG,
MacDonald JK, Chande N, Sandborn WJ and Feagan BG: C-reactive
protein, fecal calprotectin, and stool lactoferrin for detection of
endoscopic activity in symptomatic inflammatory bowel disease
patients: a systematic review and meta-analysis. Am J
Gastroenterol. 110:802–819; quiz 820. 2015.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Lobatón T, Rodríguez-Moranta F, Lopez A,
Sánchez E, Rodríguez-Alonso L and Guardiola J: A new rapid
quantitative test for fecal calprotectin predicts endoscopic
activity in ulcerative colitis. Inflamm Bowel Dis. 19:1034–1042.
2013.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Weber J, Ueberschlag ME, Prica M, Kräuchi
S, Reinhard C and Jermann T: Validation of a smartphone-based
patient monitoring system measuring Calprotectin as the therapy
follow-up marker. J Crohn's Colitis. 9 (Suppl 1):S212–S213.
2015.
|
|
35
|
Wei SC, Tung CC, Weng MT and Wong JM:
Experience of patients with inflammatory bowel disease in using a
home fecal calprotectin test as an objective reported outcome for
self-monitoring. Intest Res. 16:546–553. 2018.PubMed/NCBI View Article : Google Scholar
|
